Merck, BMS Score Separate Late-Stage Victories in Bladder Cancer at ESMO

Merck and Bristol Myers Squibb presented Phase III readouts for bladder cancer at the European Society for Medical Oncology Congress 2023, both touting strong survival benefits for their respective PD-1 blockers.